Convalescent Plasma to Stem Coronavirus: A Randomized Controlled Double-Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 non-immune plasma) Among Adults Exposed to COVID-19 (CSSC-001)

This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as prophylaxis following exposure to COVID-19. Adults 18 years of age and older with high-risk exposure and at higher risk for severe illness and/or who are health care personnel with high-risk exposure may participate. We will randomize 150 eligible subjects in a 1:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or control (SARS-CoV-2 non-immune plasma). Identifier:

NOTICE: Online training and downloadable documentation for the CSSC 001 and 004 Trials has been moved to Please register for the new site for access to these. Any already completed trainings will be filed in the eTMF and do not need to be re-taken.